Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

EJJB Pharma > Pharma Topic List B > Flashcards

Pharma Topic List B Flashcards

1
Q

B.3. Cholinomimetics - Drugs

A

carbachol
pilocarpine
neostigmine
pyridostigmine
rivastigmine
edrophonium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

B.3. Cholinomimetics - Effects

A

i.e. parasympathomimetics – Rest and Digest
Eye - contraction of iris sphincter and ciliary m.
Salivary - inc secretion
Heart - inc vagal - negative chronotropy, dromotropy, inotropy
BV - dec BP - smooth muscle relaxation
Lungs - Bronchoconstriction
Stomach - inc gastric secretion
Intestine - inc motility
Urinary Tract - alleviate retention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

B.3 Cholinmemtics - AChEi poisoning

A

DUMBBELS
D - diarrhea
U - urination
M - miosis
B - bradycardia
B - bronchoconstriction
E - excitation - CNS, muscles
L - lacrimation
S - secretion - sweating, salivation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

carbachol

A

Is a synthetic choline ester
Direct acting cholinomemtic that is highly resistant to AchE hydrolysis

Acts on both N and M - not specific so rarely used
4˚ amine - no BBB
Topical - eyedrops
t1/2= 1 hr

tx: Acute Angle Glaucoma - opens canal of Schlemm

SE - CV and GI effect - stimulates and then depresses
N-R can cause release of E from adrenal medulla

B.3. Cholinomimetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

pilocarpine

A

Direct acting Cholinomimetic - Alkaloid so it is specific for muscarinic - Muscarinic Agonist
3˚ amine Yes BBB

Resistance to AchE hydrolysis
PO (eyedrops), Parentral
DoA - 30 min - 2h

Tx - Xerostoma from Sjøgren - systemic
DoC - glaucoma

OD- Antidote Atropine

B.3. Cholinomimetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

neostigmine

A

Indirect Acting Cholinomimetic
Non-competitive AchEi
4˚amine - no BBB

its a carbamate
main site of action is NMJ
IV - poor absorption in GI

tx: non-obstructive ileus, urinary retention
Used as an antidote for non-depolarizing curare like drugs post-op

CI - intestinal or urinary obstruction

B.3. Cholinomimetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

pyridostigmine

A

Indirect acting - Non-competitive AchEi
4˚amine - NO BBB
PO
DoA = 3-6hr
Main site of action - NMJ

tx: DoC for Myasthenia Gravis
paralytic ileus, urinary bladder atony
can be used against nerve gases

B.3. Cholinomimetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

rivastigmine

A

Non-Competitive AchEi - Indirect acting Cholinomemtic

Long acting t1/2 = ±70 hr
lipid soluble - YES BBB
hydrolyzed to carbamylated metabolite - no interactions

tx: transdermal patch - Alzheimer’s
first line drug with Donepezil, Galantamine
can delay the progession but cannot stop the disease

SE - GI distresss, cholinergic sym subside with continuing use

B.3. Cholinomimetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

edrophonium

A

Competitive AchEi

Short acting t1/2 = 5-15 mins with rapid renal elimination
to short for therapeutic use
PO
4˚amine - limited to periphery

Used: Tensilon test for diagnosis of Myasthenia Gravis

If too much given - antidote with atropine

B.3. Cholinomimetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

B.4. Muscarinic receptor blocking drugs

A

atropine
scopolamine
butyl-scopolamine
ipratropium
procyclidine
solifenacin
cyclopentolate
tiotropium
oxybutinine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

atropine

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

scopolamine

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

butyl-scopolamine

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ipratropium

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

procyclidine

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

solifenacin

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

cyclopentolate

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

tiotropium

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

oxybutinine

A

B.4. Muscarinic receptor blocking drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

B.5. Catecholamines - Drugs

A

epinephrine
norepinephrine
dopamine
isoprenalin
dobutamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

epinephrine

A

B.5. Catecholamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

norepinephrine

A

B.5. Catecholamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

dopamine

A

B.5. Catecholamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

isoprenalin

A

B.5. Catecholamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
dobutamine
B.5. Catecholamines
26
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors - Drugs
ephedrine phenylephrine clonidin rilmenidine methyldopa oxymetazoline
27
ephedrine
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors
28
phenylephrine
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors
29
clonidin
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors
30
rilmenidine
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors
31
methyldopa
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors
32
oxymetazoline
B.6. Indirect sympathomimetics. Selective Alpha2-agonists and drugs acting on the imidazoline receptors
33
B.7. alpha-receptor antagonists - Drugs
prazosin doxazosin tamsulozin urapidil carvedilol phentolamine
34
prazosin
B.7. alpha-receptor antagonists
35
doxazosin
B.7. alpha-receptor antagonists
36
tamsulozin
B.7. alpha-receptor antagonists
37
urapidil
B.7. alpha-receptor antagonists
38
carvedilol
B.7. alpha-receptor antagonists
39
phentolamine
B.7. alpha-receptor antagonists
40
B.8. Beta-receptor antagonists - Drugs
propranolol pindolol carvedilol timolol sotalol metoprolol bisoprolol nebivolol esmolol
41
propranolol
B.8. Beta-receptor antagonists
42
pindolol
B.8. Beta-receptor antagonists
43
carvedilol
B.8. Beta-receptor antagonists
44
timolol
B.8. Beta-receptor antagonists
45
sotalol
B.8. Beta-receptor antagonists
46
metoprolol
B.8. Beta-receptor antagonists
47
bisoprolol
B.8. Beta-receptor antagonists
48
nebivolol
B.8. Beta-receptor antagonists
49
esmolol
B.8. Beta-receptor antagonists
50
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin - Drugs
baclofen tolperisone diazepam tizanidine dantrolene botulinum toxin
51
baclofen
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin
52
tolperisone
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin
53
diazepam
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin
54
tizanidine
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin
55
dantrolene
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin
56
botulinum toxin
B.9. Centrally acting skeletal muscle relaxants (spasmolytics). Dantrolene. Botulinum toxin
57
B.10. Skeletal muscle relaxants acting on the neuromuscular junction - Drugs
atracurium cisatracurium mivacurium pipecuronium rocuronium succynylcholine (suxamethonium)
58
atracurium
B.10. Skeletal muscle relaxants acting on the neuromuscular junction
59
cisatracurium
B.10. Skeletal muscle relaxants acting on the neuromuscular junction
60
mivacurium
B.10. Skeletal muscle relaxants acting on the neuromuscular junction
61
pipecuronium
B.10. Skeletal muscle relaxants acting on the neuromuscular junction
62
rocuronium
B.10. Skeletal muscle relaxants acting on the neuromuscular junction
63
succynylcholine (suxamethonium)
B.10. Skeletal muscle relaxants acting on the neuromuscular junction
64
B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD. - Drugs
salbutamol terbutaline fenoterol salmeterol formoterol ipratropium tiotropium theophyllin
65
B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD. - Pharma of Bronchial Asthma
chronic inflam disease of airways with bronchoconstriction, dyspnea, cough, chest rightness, wheezing. Goal of tx – reduce intensity and frequency of sympt and limitation caused by them. Quick relief, long term – reverse and prevent airway inflam. Steps to tx – 1. Assess severity and start tx accord to guideline. 2. Inc intensity of tx stepwise until well controlled 3. Dec dose of anti-inflam gradually. 1st stage – mild – SABA inhaler, or anitmusc inhal or oral SABA – symps 1x week, nighttime 2x/month FEV1>80%. 2nd stage – mild, persistent – reliever + small dose steroid inhaler or leukotriene inhib – symp 2x/week more than 2x night and FEV1>80%. 3rd stage – moderate, persistent. Reliever+small dose steroid+LABA – daily symp and FEV1 60-80%. 4th stage – severe and persistent. Reliever+med/high dose steroid +LABA.
66
B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD. - Pharma of COPD
chronic irreversible obstruction of airflow that is progressive. Tx depends on patient category. A – SAMA/SABA can add LABA or theophylline. B – LAMA/LABA can add SABA or theophylline. C-ICS+LABA can add PDE4 inhibitor or theophylline. D – ICS+LABA can add PDE4i, carbocysteine or theophylline. ICS inhaled corticosteroids
67
salbutamol
Short acting beta2 agonist – Gs – inc [cAMP] – smooth m relax – bronchodilation T1/2 – 4 hr, OoA 5 min. aerosol, nebulizer, parenteral. TX – asthma, COPD, no prophylaxis. SE – tachycardia, tremor, arrhythmia B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
68
terbutaline
Short acting beta2 agonist – Gs – inc [cAMP] – smooth m relax – bronchodilation T1/2 – 4 hr, OoA 5 min. aerosol, nebulizer, parenteral. TX – asthma, COPD, no prophylaxis. SE – tachycardia, tremor, arrhythmia B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
69
fenoterol
Short acting beta2 agonist – Gs – inc [cAMP] – smooth m relax – bronchodilation T1/2 – 4 hr, OoA 5 min. aerosol, nebulizer, parenteral. TX – asthma, COPD, no prophylaxis. SE – tachycardia, tremor, arrhythmia B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
70
salmeterol
Long acting beta2 agonist. DoA 12-24 hr. PO, aerosol, nebulizer, parenteral. TX – bronchodilation in asthma, COPD, prophylaxis – beneficial when used with corticosteroids. SE – tachycardia, tremor, arrythmia B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
71
formoterol
Long acting beta2 agonist. DoA 12-24 hr. PO, aerosol, nebulizer, parenteral. TX – bronchodilation in asthma, COPD, prophylaxis – beneficial when used with corticosteroids. SE – tachycardia, tremor, arrythmia B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
72
ipratropium
SAMA – muscarinic antagonist. Competitive inhibitor of M3R (Gq) – prevents bronchoconstriction mediated by vagal discharge. Aerosol. Onset <15 min DoA 4-6h – admin 3/day. TX – asthma, COPD – beneficial for patients with cardiac disease. SE – dry mouth, cough B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
73
tiotropium
LAMA – M3 antagonist. Aerosol. Longer acting. TX – asthma, COPD B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
74
theophyllin
PDE3 inhibitor – prevents the breakdown of cAMP – inc cAMP in smooth muscle cells leading to bronchodilation. Methylaxanthine derivative. PO, slow release. DOA 12 hr. hepatic CYP450. TX – asthma – prophylaxis in nocturnal attacks, AHF, anti-inflamm. SE – GI distress, insomnia, tremor, anorexia, seizures, cardiac stimulation chon and ino, arrythmia, CNS B.11. Selective Beta2-stimulants and other bronchodilators. Pharmacotherapy of bronchial asthma and COPD.
75
B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants - Drugs
prednisolone methylprednisolon fluticazone budesonide montelukast omalizumab codein butamirate prenoxdiazine acetylcystein bromhexin
76
prednisolone
inhaled GC. TX – severe asthma – can use systemic PO. Most effective anti-inflam agent used in asthma. Inhibits PLA2 – dec COX – dec inflame mediators, dec inflame cells in airway, dec eosinophils dec activated T cells and mast cells. Inc beta-2 R expression. SE – infection – oral candiasis, hyperglycemia, Cushings B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
77
methylprednisolon
inhaled GC. TX – severe asthma – can use systemic PO. Most effective anti-inflam agent used in asthma. Inhibits PLA2 – dec COX – dec inflame mediators, dec inflame cells in airway, dec eosinophils dec activated T cells and mast cells. Inc beta-2 R expression. SE – infection – oral candiasis, hyperglycemia, Cushings B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
78
fluticazone
inhaled GC for asthma and COPD B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
79
budesonide
Topical GC tx bronchial asthma, allergic rhinitis. Enema- IBD B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
80
montelukast
selective antagonist of CysLT1 Receptor which dec LDT4 (leukotriene D4). Prevents Leukotrienes binding to receptor – dec bronchoconstriction and inflamm. Smooth muscle relaxant. TX – exercise induced asthma, long term maintenance. SE – upper resp infect, headache, fever. B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
81
omalizumab
(humanized) – Anti-IgE antibody. Binds the Fc portion of the IgE Ab – binding to high affinity R on mast cells is prevented – dec inflamm response to inhaled antigens. EXPENSIVE. Parenteral. TX – prophylaxis of severe refractory asthma, that doesn’t respond to other drugs B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
82
codein
mu opioid R agonist. Antitussive, analgesic effect. Weak semi-synthetic morphine agonist – suppresses cough reflex. 10% of codeine is transformed into morphine by CYP2D6. SE – constipation, dependence B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
83
butamirate
non-opioid centrally acting antitussive – suppresses cough reflex. PO. Peripheral effect – bronchodilation, suppress inflamm. TX – cough B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
84
prenoxdiazine
antitussive that acts on periphery. Dec receptor sensitivity, dec sensitivity of afferent nerves, inhibit cough reflex. Works as local anesthetic in bronchoscopy. B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
85
acetylcystein
mucolytic expectorant. Cleaves mucopolysacc and glucopro of mucus – diluting the mucus and dec viscosity. Has thiol group – cleaves disulfide bridges. TX – CF, chronic bronchitis, bronchiectasis. B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
86
bromhexin
mucolytic expectorant. Inc the production of serous fluid in the resp tract, which makes phlegm thinner. PO TX – CF, chronic bronchitis, bronchiectasis B.12. Antiinflammatory agents used in bronchial asthma. Antitussive agents and expectorants
87
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine - Drugs
vinpocetin nicergolin cilostazol pentoxifyllin Ca-dobesilate sumatriptan galkanezumab cinnarizin propranolol verapamil carbamazepine valproate imipramine
88
vinpocetin
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
89
nicergolin
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
90
cilostazol
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
91
pentoxifyllin
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
92
Ca-dobesilate
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
93
sumatriptan
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
94
galkanezumab
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
95
cinnarizin
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
96
propranolol
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
97
verapamil
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
98
carbamazepine
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
99
valproate
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
100
imipramine
B.13. Drugs used for the treatment of peripheral vascular diseases. Therapy of migraine
101
B.14. Drugs used for treatment of heart failure I: Drugs decreasing the load on the heart. Drugs of acute cardiac failure. Pharmacotherapy of chronic heart failure. - drugs
ACE-inhibitors, diuretics, beta-blockers
102
B.15. Drugs used for treatment of heart failure II: Positive inotropic agents. Pharmacotherapy of acute heart failure. - Drugs
digoxin digitoxin milrinone levosimendan dobutamine
103
digoxin
B.15. Drugs used for treatment of heart failure II: Positive inotropic agents. Pharmacotherapy of acute heart failure
104
digitoxin
B.15. Drugs used for treatment of heart failure II: Positive inotropic agents. Pharmacotherapy of acute heart failure
105
milrinone
B.15. Drugs used for treatment of heart failure II: Positive inotropic agents. Pharmacotherapy of acute heart failure
106
levosimendan
B.15. Drugs used for treatment of heart failure II: Positive inotropic agents. Pharmacotherapy of acute heart failure
107
dobutamine
B.15. Drugs used for treatment of heart failure II: Positive inotropic agents. Pharmacotherapy of acute heart failure
108
B.16. Antiarrhytmic agents - Drugs
lidocaine propafenone esmolol amiodarone sotalol verapamil adenozine digoxin Mg++
109
lidocaine
B.16. Antiarrhytmic agents
110
propafenone
B.16. Antiarrhytmic agents
111
esmolol
B.16. Antiarrhytmic agents
112
amiodarone
B.16. Antiarrhytmic agents
113
sotalol
B.16. Antiarrhytmic agents
114
verapamil
B.16. Antiarrhytmic agents
115
adenozine
B.16. Antiarrhytmic agents
116
digoxin
B.16. Antiarrhytmic agents
117
Mg++
B.16. Antiarrhytmic agents
118
B.17. Drugs used for the treatment of hypertension I: Classification of antihypertensive agents and their mechanisms of action. Pharmacotherapy of hypertension. - Drugs
sympatholytics diuretics
119
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators - Drugs
amlodipine felodipine nifedipine nimodipine verapamil dihydralazine bozentan sildenafil
120
amlodipine
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
121
felodipine
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
122
nifedipine
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
123
nimodipine
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
124
verapamil
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
125
dihydralazine
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
126
bozentan
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
127
sildenafil
B.18. Drugs used for the treatment of hypertension II: Ca++-channel blockers and other vasodilators
128
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system - Drugs
enalapril perindopril ramipril losartan valsartan valsartan + sacubitril irbesartan spironolactone eplerenon captopril
129
enalapril
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
130
perindopril
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
131
ramipril
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
132
losartan
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
133
valsartan
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
134
valsartan + sacubitril
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
135
irbesartan
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
136
spironolactone
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
137
eplerenon
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
138
captopril
B.19. Drugs used for the treatment of hypertension III: Drugs acting on the renin-angiotensin-aldosterone system
139
B.20. Drugs used for treatment of angina pectoris. Pharmacotherapy of ischemic heart disease. - Drugs
nitroglicerin isosorbid-mononitrate trimetazidine ivabradin beta-bockers and Ca-channel blockers
140
nitroglicerin
B.20. Drugs used for treatment of angina pectoris. Pharmacotherapy of ischemic heart disease.
141
isosorbid-mononitrate
B.20. Drugs used for treatment of angina pectoris. Pharmacotherapy of ischemic heart disease.
142
trimetazidine
B.20. Drugs used for treatment of angina pectoris. Pharmacotherapy of ischemic heart disease.
143
ivabradin
B.20. Drugs used for treatment of angina pectoris. Pharmacotherapy of ischemic heart disease.
144
B21. Agents used in dyslipidaemias. - Drugs
simvastatin atorvastatin rosuvastatin ezetimib fenofibrate colesevelam
145
simvastatin
B21. Agents used in dyslipidaemias
146
atorvastatin
B21. Agents used in dyslipidaemias
147
rosuvastatin
B21. Agents used in dyslipidaemias
148
ezetimib
B21. Agents used in dyslipidaemias
149
fenofibrate
B21. Agents used in dyslipidaemias
150
colesevelam
B21. Agents used in dyslipidaemias
151
B.22. Potassium excreting (wasting) diuretics - Drugs
acetazolamide hydrochlorothiazide indapamide furosemide etacrynic acid
152
acetazolamide
B.22. Potassium excreting (wasting) diuretics
153
hydrochlorothiazide
B.22. Potassium excreting (wasting) diuretics
154
indapamide
B.22. Potassium excreting (wasting) diuretics
155
furosemide
B.22. Potassium excreting (wasting) diuretics
156
etacrynic acid
B.22. Potassium excreting (wasting) diuretics
157
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics - Drugs
spironolactone eplerenone amiloride tolvaptan mannitol glycerol
158
spironolactone
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics
159
eplerenone
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics
160
amiloride
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics
161
tolvaptan
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics
162
mannitol
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics
163
glycerol
23. Potassium sparing diuretics, ADH antagonists, osmotic diuretics
164
B.24. Histamine and antihistamines. - drugs
promethazine diphenhydramine cetirizine levocetirizine loratadine desloratadine dimetinden fexofenadin
165
promethazine
B.24. Histamine and antihistamines
166
diphenhydramine
B.24. Histamine and antihistamines
167
cetirizine
B.24. Histamine and antihistamines
168
levocetirizine
B.24. Histamine and antihistamines
169
loratadine
B.24. Histamine and antihistamines
170
desloratadine
B.24. Histamine and antihistamines
171
dimetinden
B.24. Histamine and antihistamines
172
fexofenadin
B.24. Histamine and antihistamines
173
B.25. Natural opiates, opioid receptors - Drugs
morphine codeine
174
morphine
B.25. Natural opiates, opioid receptors
175
codeine
B.25. Natural opiates, opioid receptors
176
B.26. Semisynthetic and synthetic opiates - Drugs
hydromorphone dihydrocodeine oxycodone buprenorphine nalbuphine meperidine =(pethidine) fentanyl methadone tramadol diphenoxylate loperamide naloxone methyl-naltrexone
177
hydromorphone
B.26. Semisynthetic and synthetic opiates
178
dihydrocodeine
B.26. Semisynthetic and synthetic opiates
179
oxycodone
B.26. Semisynthetic and synthetic opiates
180
buprenorphine
B.26. Semisynthetic and synthetic opiates
181
nalbuphine
B.26. Semisynthetic and synthetic opiates
182
meperidine =(pethidine)
B.26. Semisynthetic and synthetic opiates
183
fentanyl
B.26. Semisynthetic and synthetic opiates
184
methadone
B.26. Semisynthetic and synthetic opiates
185
tramadol
B.26. Semisynthetic and synthetic opiates
186
diphenoxylate
B.26. Semisynthetic and synthetic opiates
187
loperamide
B.26. Semisynthetic and synthetic opiates
188
naloxone
B.26. Semisynthetic and synthetic opiates
189
methyl-naltrexone
B.26. Semisynthetic and synthetic opiates
190
B.27. General properties of NSAIDs. Acetylsalicylic acid. - Drugs
acetylsalicylsav colchicin allopurinol rasburicase
191
acetylsalicylsav
B.27. General properties of NSAIDs. Acetylsalicylic acid.
192
colchicin
B.27. General properties of NSAIDs. Acetylsalicylic acid.
193
allopurinol
B.27. General properties of NSAIDs. Acetylsalicylic acid.
194
rasburicase
B.27. General properties of NSAIDs. Acetylsalicylic acid.
195
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain. - Drugs
metamizole naproxen ibuprofen ketoprofen dexketoprofen phenylbutazone indomethacin diclofenac meloxicam celecoxib paracetamol
196
metamizole
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
197
naproxen
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
198
ibuprofen
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
199
ketoprofen
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
200
dexketoprofen
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
201
phenylbutazone
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
202
indomethacin
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
203
diclofenac
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
204
meloxicam
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
205
celecoxib
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
206
paracetamol
B.28. NSAIDs, except acetylsalicylic acid. Non-opioid and adjuvant analgesics. Drugs used for treatment of gout. Treatment strategy of pain.
207
B.29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases. - Drugs
cyclophosphamide methotrexate leflunomide azathioprin mycophenolate-mofetil
208
cyclophosphamide
B.29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases.
209
methotrexate
B.29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases.
210
leflunomide
B.29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases.
211
azathioprin
B.29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases.
212
mycophenolate-mofetil
B.29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases.
213
B.30. Immunopharmacology II. (Inhibitors of cytokine gene expression, 5-ASA derivatives) - drugs
cyclosporin A tacrolimus sirolimus tofacitinib sulfasalazine
214
cyclosporin A
B.30. Immunopharmacology II. (Inhibitors of cytokine gene expression, 5-ASA derivatives)
215
tacrolimus
B.30. Immunopharmacology II. (Inhibitors of cytokine gene expression, 5-ASA derivatives)
216
sirolimus
B.30. Immunopharmacology II. (Inhibitors of cytokine gene expression, 5-ASA derivatives)
217
tofacitinib
B.30. Immunopharmacology II. (Inhibitors of cytokine gene expression, 5-ASA derivatives)
218
sulfasalazine
B.30. Immunopharmacology II. (Inhibitors of cytokine gene expression, 5-ASA derivatives)
219
B.31. Immunopharmacology III. (Antibodies and fusion proteins) - Drugs
ATG (antithymocyte-globulin) rituximab infliximab adalimumab tocilizumab ustekinumab natalizumab dupilumab abatacept
220
ATG (antithymocyte-globulin)
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
221
rituximab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
222
infliximab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
223
adalimumab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
224
tocilizumab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
225
ustekinumab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
226
natalizumab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
227
dupilumab
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
228
abatacept
B.31. Immunopharmacology III. (Antibodies and fusion proteins)
229
B.32. Cancer chemotherapy I (antimetabolites) - Drugs
5-fluorouracyl capecitabine cytarabine 6-merkaptopurine methotrexate pemetrexed
230
5-fluorouracyl
B.32. Cancer chemotherapy I (antimetabolites)
231
capecitabine
B.32. Cancer chemotherapy I (antimetabolites)
232
cytarabine
B.32. Cancer chemotherapy I (antimetabolites)
233
6-merkaptopurine
B.32. Cancer chemotherapy I (antimetabolites)
234
methotrexate
B.32. Cancer chemotherapy I (antimetabolites)
235
pemetrexed
B.32. Cancer chemotherapy I (antimetabolites)
236
B.33. Cancer chemotherapy II (alkylating agents) - Drugs
cyclophosphamide dacarbazine temozolomide cisplatine oxaliplatin dactinomycin bleomycin
237
cyclophosphamide
B.33. Cancer chemotherapy II (alkylating agents)
238
dacarbazine
B.33. Cancer chemotherapy II (alkylating agents)
239
temozolomide
B.33. Cancer chemotherapy II (alkylating agents)
240
cisplatine
B.33. Cancer chemotherapy II (alkylating agents)
241
oxaliplatin
B.33. Cancer chemotherapy II (alkylating agents)
242
dactinomycin
B.33. Cancer chemotherapy II (alkylating agents)
243
bleomycin
B.33. Cancer chemotherapy II (alkylating agents)
244
B.34. Cancer chemotherapy III (Topisomerase inhibitors. Inhibitors of mitotic spindle) - Drugs
irinotecan etoposide doxorubicin vincristine docetaxel
245
irinotecan
B.34. Cancer chemotherapy III (Topisomerase inhibitors. Inhibitors of mitotic spindle)
246
etoposide
B.34. Cancer chemotherapy III (Topisomerase inhibitors. Inhibitors of mitotic spindle)
247
doxorubicin
B.34. Cancer chemotherapy III (Topisomerase inhibitors. Inhibitors of mitotic spindle)
248
vincristine
B.34. Cancer chemotherapy III (Topisomerase inhibitors. Inhibitors of mitotic spindle)
249
docetaxel
B.34. Cancer chemotherapy III (Topisomerase inhibitors. Inhibitors of mitotic spindle)
250
B.35. Cancer chemotherapy IV. (Hormonal agents) - Drugs
tamoxifen anastrozole goserelin degarelix bicalutamide prednisolone octreotide
251
tamoxifen
B.35. Cancer chemotherapy IV. (Hormonal agents)
252
anastrozole
B.35. Cancer chemotherapy IV. (Hormonal agents)
253
goserelin
B.35. Cancer chemotherapy IV. (Hormonal agents)
254
degarelix
B.35. Cancer chemotherapy IV. (Hormonal agents)
255
bicalutamide
B.35. Cancer chemotherapy IV. (Hormonal agents)
256
prednisolone
B.35. Cancer chemotherapy IV. (Hormonal agents)
257
octreotide
B.35. Cancer chemotherapy IV. (Hormonal agents)
258
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors) - Drugs
imatinib gefitinib erlotinib lapatinib sunitinib ibrutinib crizotinib bortezomib dabrafenib+ trametinib everolimus tretinoin
259
imatinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
260
gefitinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
261
erlotinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
262
lapatinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
263
sunitinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
264
ibrutinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
265
crizotinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
266
bortezomib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
267
dabrafenib+ trametinib
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
268
everolimus
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
269
tretinoin
B.36. Cancer chemotherapy V. (Small molecule signal transduction inhibitors)
270
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors) - Drugs
trastuzumab (-emtansin) panitumumab rituximab bevacizumab alfa-interferon aldesleukin pembrolizumab
271
trastuzumab (-emtansin)
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)
272
panitumumab
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)
273
rituximab
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)
274
bevacizumab
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)
275
alfa-interferon
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)
276
aldesleukin
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)
277
pembrolizumab
37. Cancer chemotherapy VI. (Large molecule signal transduction inhibitors)

EJJB Pharma (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions